Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells

Overview

Journal Mol Cancer Ther

Date 2018 Oct 10

PMID 30297360

Citations 21

Authors

Jun Dong

Zeyu Wu

Dan Wang

Laura E Pascal

Joel B Nelson

Peter Wipf

Zhou Wang

Affiliations

Soon will be listed here.

Abstract

The androgen receptor (AR) is a key driver and therapeutic target in androgen-sensitive prostate cancer, castration-resistant prostate cancer (CRPC), and CRPC resistant to abiraterone and enzalutamide, two second-generation inhibitors of AR signaling. Because current AR inhibitors target a functioning C-terminal ligand-binding domain (LBD), the identification and characterization of cofactors interacting with the N-terminal domain (NTD) of AR may lead to new approaches to target AR signaling in CRPC. Using a pull-down approach coupled with proteomics, we have identified Hsp70 as a cofactor for the NTD of AR in prostate cancer cells. Hsp70 inhibition using siRNA or small molecules indicated that Hsp70 played an important role in the expression and transactivation of endogenous AR. Prostate-specific antigen (PSA) promoter/enhancer-driven luciferase assays showed that Hsp70 was also required for transactivation of AR mutant lacking LBD. Furthermore, clonogenic assays showed that an Hsp70 inhibitor, either alone or in synergy with enzalutamide, can inhibit the proliferation of 22Rv1, a widely used enzalutamide-resistant CRPC prostate cancer cell line. These findings suggest that Hsp70 is a potential therapeutic target for the treatment of enzalutamide-resistant CRPC.

Citing Articles

Advances in the structures, mechanisms and targeting of molecular chaperones.

Gu J, He Y, He C, Zhang Q, Huang Q, Bai S Signal Transduct Target Ther. 2025; 10(1):84.

PMID: 40069202 PMC: 11897415. DOI: 10.1038/s41392-025-02166-2.

A mitochondrial outer membrane protein TOMM20 maintains protein stability of androgen receptor and regulates AR transcriptional activity in prostate cancer cells.

Yin L, Dai Y, Wang Y, Liu S, Ye Y, Fu Y Oncogene. 2025; .

PMID: 40044984 DOI: 10.1038/s41388-025-03328-w.

N-terminal domain of androgen receptor is a major therapeutic barrier and potential pharmacological target for treating castration resistant prostate cancer: a comprehensive review.

Chen Y, Lan T Front Pharmacol. 2024; 15:1451957.

PMID: 39359255 PMC: 11444995. DOI: 10.3389/fphar.2024.1451957.

International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023.

Burris T, de Vera I, Cote I, Flaveny C, Wanninayake U, Chatterjee A Pharmacol Rev. 2023; 75(6):1233-1318.

PMID: 37586884 PMC: 10595025. DOI: 10.1124/pharmrev.121.000436.

AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer.

Yin L, Ye Y, Zou L, Lin J, Dai Y, Fu Y J Exp Clin Cancer Res. 2023; 42(1):204.

PMID: 37563661 PMC: 10413764. DOI: 10.1186/s13046-023-02776-0.

References

Huang F, Zeng X, Kim W, Balasubramani M, Fortian A, Gygi S . Lysine 63-linked polyubiquitination is required for EGF receptor degradation. Proc Natl Acad Sci U S A. 2013; 110(39):15722-7. PMC: 3785728. DOI: 10.1073/pnas.1308014110. View

Kityk R, Kopp J, Sinning I, Mayer M . Structure and dynamics of the ATP-bound open conformation of Hsp70 chaperones. Mol Cell. 2012; 48(6):863-74. DOI: 10.1016/j.molcel.2012.09.023. View

Manos-Turvey A, Al-Ashtal H, Needham P, Hartline C, Prichard M, Wipf P . Dihydropyrimidinones and -thiones with improved activity against human polyomavirus family members. Bioorg Med Chem Lett. 2016; 26(20):5087-5091. PMC: 5050167. DOI: 10.1016/j.bmcl.2016.08.080. View

Holzbeierlein J, Lal P, Latulippe E, Smith A, Satagopan J, Zhang L . Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol. 2003; 164(1):217-27. PMC: 1602218. DOI: 10.1016/S0002-9440(10)63112-4. View

Dimopoulos M, Mitsiades C, Anderson K, Richardson P . Tanespimycin as antitumor therapy. Clin Lymphoma Myeloma Leuk. 2011; 11(1):17-22. DOI: 10.3816/CLML.2011.n.002. View

Donovan M, Osman I, Khan F, Vengrenyuk Y, Capodieci P, Koscuiszka M . Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. BJU Int. 2009; 105(4):462-7. DOI: 10.1111/j.1464-410X.2009.08747.x. View

Ryan C, Smith M, de Bono J, Molina A, Logothetis C, de Souza P . Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2012; 368(2):138-48. PMC: 3683570. DOI: 10.1056/NEJMoa1209096. View

Massey A, Williamson D, Browne H, Murray J, Dokurno P, Shaw T . A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells. Cancer Chemother Pharmacol. 2009; 66(3):535-45. DOI: 10.1007/s00280-009-1194-3. View

Zhu M, Horbinski C, Garzotto M, Qian D, Beer T, Kyprianou N . Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010; 70(20):7992-8002. PMC: 2978028. DOI: 10.1158/0008-5472.CAN-10-0585. View

10.

Hartl F, Bracher A, Hayer-Hartl M . Molecular chaperones in protein folding and proteostasis. Nature. 2011; 475(7356):324-32. DOI: 10.1038/nature10317. View

11.

Munro S, Pelham H . An Hsp70-like protein in the ER: identity with the 78 kd glucose-regulated protein and immunoglobulin heavy chain binding protein. Cell. 1986; 46(2):291-300. DOI: 10.1016/0092-8674(86)90746-4. View

12.

Zhu X, Zhao X, Burkholder W, Gragerov A, Ogata C, GOTTESMAN M . Structural analysis of substrate binding by the molecular chaperone DnaK. Science. 1996; 272(5268):1606-14. PMC: 5629921. DOI: 10.1126/science.272.5268.1606. View

13.

Moses M, Kim Y, Rivera-Marquez G, Oshima N, Watson M, Beebe K . Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer. Cancer Res. 2018; 78(14):4022-4035. PMC: 6050126. DOI: 10.1158/0008-5472.CAN-17-3728. View

14.

Scher H, Beer T, Higano C, Anand A, Taplin M, Efstathiou E . Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010; 375(9724):1437-46. PMC: 2948179. DOI: 10.1016/S0140-6736(10)60172-9. View

15.

Hu R, Dunn T, Wei S, Isharwal S, Veltri R, Humphreys E . Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009; 69(1):16-22. PMC: 2614301. DOI: 10.1158/0008-5472.CAN-08-2764. View

16.

Sramkoski R, Pretlow 2nd T, Giaconia J, Pretlow T, Schwartz S, Sy M . A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim. 1999; 35(7):403-9. DOI: 10.1007/s11626-999-0115-4. View

17.

Krause W, Shafi A, Nakka M, Weigel N . Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells. Int J Biochem Cell Biol. 2014; 54:49-59. PMC: 4160387. DOI: 10.1016/j.biocel.2014.06.013. View

18.

Jung M, Ouk S, Yoo D, Sawyers C, Chen C, Tran C . Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem. 2010; 53(7):2779-96. PMC: 3180999. DOI: 10.1021/jm901488g. View

19.

Huggins C, Hodges C . Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002; 167(2 Pt 2):948-51; discussion 952. View

20.

Boudadi K, Antonarakis E . Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. Clin Med Insights Oncol. 2016; 10(Suppl 1):1-9. PMC: 4798019. DOI: 10.4137/CMO.S34534. View